Cravath Publishes Summer 2026 Issue of Alumni Journal
Cravath represented Citibank, N.A., as administrative agent, in connection with the arrangement of $550 million of credit facilities made available to Blackstone / GSO Secured Lending Fund, an externally managed and non‑diversified closed‑end investment company. The transaction closed on June 15, 2020.
The Cravath team included partner Stephen M. Kessing and associates Janice T. P. Martindale and Vanessa Isler on banking matters, and partner J. Leonard Teti II and associates Peter W. Rogers and Luis Calderon-Gomez on tax matters.
Deals & Cases
July 06, 2026
Cravath represented the agent, mandated lead arrangers, and lenders in connection with the repricing of UVEX GROUP GmbH’s €400 million term loan facility and €50 million term loan add-on. UVEX GROUP GmbH is a portfolio company of Warburg Pincus. The transaction closed on June 19, 2026.
Deals & Cases
April 06, 2026
Cravath represented the administrative agent, joint lead arrangers and joint bookrunners in connection with $1.35 billion of credit facilities made available to subsidiaries of Versigent Limited, a global leader in the design, development and manufacture of low voltage and high voltage electrical architectures and the holding company for Aptiv PLC’s Electrical Distribution Systems segment, which Aptiv PLC spun off into a separate, independent, publicly traded company. The proceeds were used to partially finance the spin‑off. The credit facilities consisted of a $500 million term loan facility and an $850 million revolving credit facility. The transaction closed on November 26, 2025.
Deals & Cases
February 20, 2026
Cravath represented First Solar, Inc. in connection with its $1.5 billion revolving credit facility. First Solar is America’s leading photovoltaic solar technology and manufacturing company, and the only US‑headquartered company among the world’s largest solar manufacturers. The transaction closed on February 13, 2026.
Deals & Cases
January 08, 2026
Cravath represented the administrative agent, joint lead arrangers and joint bookrunners in connection with $3.5 billion of credit facilities made available to Genmab, a leading international biotechnology company, and one of its wholly‑owned subsidiaries, Genmab Finance LLC, as part of the financing transactions undertaken in connection with its acquisition of Merus N.V., a leading oncology company developing innovative antibody therapeutics. The credit facilities consisted of a $2 billion term loan “B” facility, a $1 billion term loan “A” facility and a $500 million revolving credit facility. The transaction closed on December 12, 2025.
Celebrating 200 years of partnership. In 2019, we celebrated our bicentennial. Our history mirrors that of our nation. Integral to our story is our culture.
Attorney Advertising. ©2026 Cravath, Swaine & Moore LLP.